Last reviewed · How we verify
Additional injection of 0,5% levobupivacaine.
Additional injection of 0,5% levobupivacaine. is a Small molecule drug developed by University Hospital, Ghent. It is currently FDA-approved.
At a glance
| Generic name | Additional injection of 0,5% levobupivacaine. |
|---|---|
| Sponsor | University Hospital, Ghent |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Trial to Compare Femoral Nerve Block With Local Anaesthetic Injection for Post-operative Pain After Knee Replacement. (NA)
- Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Third Trimester Medical Termination of Pregnancy Analgesia : a Randomized Study. (PCEA-IMG) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Additional injection of 0,5% levobupivacaine. CI brief — competitive landscape report
- Additional injection of 0,5% levobupivacaine. updates RSS · CI watch RSS
- University Hospital, Ghent portfolio CI
Frequently asked questions about Additional injection of 0,5% levobupivacaine.
What is Additional injection of 0,5% levobupivacaine.?
Additional injection of 0,5% levobupivacaine. is a Small molecule drug developed by University Hospital, Ghent.
Who makes Additional injection of 0,5% levobupivacaine.?
Additional injection of 0,5% levobupivacaine. is developed and marketed by University Hospital, Ghent (see full University Hospital, Ghent pipeline at /company/university-hospital-ghent).
What development phase is Additional injection of 0,5% levobupivacaine. in?
Additional injection of 0,5% levobupivacaine. is FDA-approved (marketed).